Challenges in the therapeutic options for the Interstitial Lung Disease: When to start? Immunosuppressant, wich one? Antifibrotic? How to evaluate effectiveness? #EULAR2019 Dr. Grutters (Netherlands) https://t.co/lPsKa1wwxE